2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Company profile
Ticker
TSVT
Exchange
Website
CEO
Mr. William D. Baird III, M.B.A.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Owl Rock Core Income Corp.
SEC CIK
Corporate docs
Subsidiaries
2seventy bio Securities Corporation ...
IRS number
863658454
TSVT stock data
Latest filings (excl ownership)
8-K
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
12 Nov 24
8-K
Results of Operations and Financial Condition
31 Oct 24
8-K
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
25 Sep 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
7 Aug 24
8-K
Results of Operations and Financial Condition
26 Jul 24
8-K
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
26 Jun 24
8-K
Unleash Time2seventy bio company presentation May 2024
11 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
8 May 24
Transcripts
TSVT
Earnings call transcript
2024 Q3
12 Nov 24
TSVT
Earnings call transcript
2024 Q2
7 Aug 24
TSVT
Earnings call transcript
2024 Q1
8 May 24
TSVT
Earnings call transcript
2023 Q4
5 Mar 24
TSVT
Earnings call transcript
2023 Q3
14 Nov 23
TSVT
Earnings call transcript
2023 Q2
14 Aug 23
TSVT
Earnings call transcript
2023 Q2
14 Aug 23
TSVT
Earnings call transcript
2023 Q1
3 May 23
TSVT
Earnings call transcript
2023 Q1
3 May 23
TSVT
Earnings call transcript
2022 Q2
10 Aug 22
Latest ownership filings
SC 13G/A
MORGAN STANLEY
6 Nov 24
4
Jessica Snow
7 Oct 24
4
Victoria Eatwell
7 Oct 24
4
Jessica Snow
16 Aug 24
144
Notice of proposed sale of securities
14 Aug 24
4
Victoria Eatwell
7 Aug 24
4
William D Baird III
3 Jul 24
4
Jessica Snow
3 Jul 24
4
Victoria Eatwell
3 Jul 24
4
Marcela V. Maus
12 Jun 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 112.30 mm | 112.30 mm | 112.30 mm | 112.30 mm | 112.30 mm | 112.30 mm |
Cash burn (monthly) | (no burn) | (no burn) | 9.02 mm | 18.14 mm | 7.71 mm | 12.51 mm |
Cash used (since last report) | n/a | n/a | 40.10 mm | 80.60 mm | 34.28 mm | 55.60 mm |
Cash remaining | n/a | n/a | 72.20 mm | 31.70 mm | 78.02 mm | 56.70 mm |
Runway (months of cash) | n/a | n/a | 8.0 | 1.7 | 10.1 | 4.5 |
Institutional ownership, Q2 2024
92.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 111 |
Opened positions | 19 |
Closed positions | 21 |
Increased positions | 37 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 182.18 bn |
Total shares | 47.61 mm |
Total puts | 9.70 k |
Total calls | 211.10 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Kynam Capital Management | 5.95 mm | $22.92 bn |
GS The Goldman Sachs Group, Inc. | 4.14 mm | $15.93 bn |
BLK BlackRock | 3.66 mm | $14.09 bn |
Vanguard | 3.63 mm | $13.97 bn |
MS Morgan Stanley | 3.27 mm | $12.59 bn |
Madison Avenue Partners | 2.56 mm | $9.87 bn |
Baker Bros. Advisors | 2.50 mm | $9.62 bn |
Newtyn Management | 2.49 mm | $9.57 bn |
Casdin Capital | 2.00 mm | $7.70 bn |
Deutsche Bank AG - Registered Shares | 1.78 mm | $6.87 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Oct 24 | Jessica Snow | Common Stock | Sell | Dispose S | No | No | 4.6488 | 679 | 3.16 k | 155,766 |
3 Oct 24 | Victoria Eatwell | Common Stock | Sell | Dispose S | No | No | 4.6488 | 1,230 | 5.72 k | 340,089 |
14 Aug 24 | Jessica Snow | Common Stock | Sell | Dispose S | No | No | 4.3194 | 7,816 | 33.76 k | 156,330 |
5 Aug 24 | Victoria Eatwell | Common Stock | Sell | Dispose S | No | No | 3.985 | 13 | 51.81 | 341,319 |
2 Jul 24 | Victoria Eatwell | Common Stock | Sell | Dispose S | No | No | 4.0178 | 12 | 48.21 | 341,332 |
1 Jul 24 | Victoria Eatwell | Common Stock | Grant | Acquire A | No | No | 0 | 245,864 | 0.00 | 341,344 |
News
2seventy bio Q3 2024 GAAP EPS $(0.19) Beats $(0.22) Estimate, Sales $13.534M Miss $15.036M Estimate
12 Nov 24
Earnings Scheduled For November 12, 2024
12 Nov 24
2seventy bio Earnings Preview
11 Nov 24
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
18 Oct 24
12 Health Care Stocks Moving In Thursday's After-Market Session
3 Oct 24
Press releases
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
12 Nov 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
10 Nov 24
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
4 Nov 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
2 Nov 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
25 Oct 24